Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
about
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsLipids, blood pressure, kidney - what was new in 2011?Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyCost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.Safety and tolerability of paricalcitol in patients with chronic kidney disease.Should monitoring of fibroblast growth factor-23 levels in dialysis patients be a part of routine clinical practice?Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.Save life and improve quality: report from the 5th Congress of International Society for Hemodialysis.Which vitamin D in CKD-MBD? The time of burning questions.Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.Total parathyroidectomy with forearm auto-transplantation improves the quality of life and reduces the recurrence of secondary hyperparathyroidism in chronic kidney disease patients.
P2860
Q24187385-4BD2903F-D27B-4022-AA4F-4A79DD460710Q35691396-0B4345BB-8151-4E02-B84C-9E63562DA207Q36129859-FA20848B-6E35-425D-A34B-C29335761638Q37506408-1861F972-3669-4B50-A9A7-CA461900CFD6Q38101995-7B865CFF-C25F-4227-A251-0EB7698AB140Q38231420-92EFB860-EBAA-495F-842E-729FBEAED0EFQ38436799-8D9BA9B2-08B0-44AD-84EC-0DE324746986Q41968095-EAE703DA-F40C-4928-AD76-AA21C56E7CAEQ42562972-E991DE02-B991-43F3-880C-E2CE4FBA174CQ42683242-726EB604-AA9F-4CCA-B747-3A01D4803748Q47547825-D3D7E2E5-954D-40E9-9EE5-67302C17A746
P2860
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Paricalcitol versus cinacalcet ...... stics of the IMPACT SHPT study
@ast
Paricalcitol versus cinacalcet ...... stics of the IMPACT SHPT study
@en
type
label
Paricalcitol versus cinacalcet ...... stics of the IMPACT SHPT study
@ast
Paricalcitol versus cinacalcet ...... stics of the IMPACT SHPT study
@en
prefLabel
Paricalcitol versus cinacalcet ...... stics of the IMPACT SHPT study
@ast
Paricalcitol versus cinacalcet ...... stics of the IMPACT SHPT study
@en
P2093
P2860
P356
P1476
Paricalcitol versus cinacalcet ...... stics of the IMPACT SHPT study
@en
P2093
Amit Sharma
David Goldsmith
Emily Dumas
Kevin J Martin
Mario Cozzolino
Markus Ketteler
Michael Amdahl
Paul Audhya
Samina Khan
Steven Marx
P2860
P304
P356
10.1093/NDT/GFR531
P407
P577
2011-09-19T00:00:00Z